The startup develops ophthalmic technology that utilizes targeted drug delivery systems to treat glaucoma and other eye diseases, including age-related macular degeneration and inherited retinal dystrophies. This technology aims to preserve and restore vision quality for patients suffering from these conditions.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for vision-threatening diseases like glaucoma, age-related macular degeneration, and inherited retinal dystrophies often fail to adequately address the underlying causes of vision loss and may have limited efficacy in preserving or restoring vision. There remains a significant unmet need for disease-modifying therapies that can effectively protect and enhance vision for patients suffering from these conditions.
Solution
Tavo Biotherapeutics is developing a new generation of targeted drug delivery systems designed to treat the root causes of vision loss in ophthalmic diseases. Their therapies aim to protect and enhance vision by delivering therapeutic agents directly to the affected tissues in the eye. By focusing on disease modification, Tavo Biotherapeutics seeks to provide more effective and long-lasting solutions for patients with glaucoma, age-related macular degeneration, and inherited retinal dystrophies. The company's approach aims to address the limitations of existing treatments and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from glaucoma, age-related macular degeneration, and inherited retinal dystrophies, as well as the ophthalmologists and retinal specialists who treat these conditions.
Features
- Targeted drug delivery to specific ocular tissues
- Focus on disease-modifying mechanisms
- Development of therapies for glaucoma-related neurodegeneration
- Development of therapies for retinal diseases